US20070275092A1 - Therapeutic composition supporting the immune system - Google Patents
Therapeutic composition supporting the immune system Download PDFInfo
- Publication number
- US20070275092A1 US20070275092A1 US11/825,407 US82540707A US2007275092A1 US 20070275092 A1 US20070275092 A1 US 20070275092A1 US 82540707 A US82540707 A US 82540707A US 2007275092 A1 US2007275092 A1 US 2007275092A1
- Authority
- US
- United States
- Prior art keywords
- vitamin
- compound
- weight
- therapeutic nutritional
- nutritional compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 34
- 239000000203 mixture Substances 0.000 title description 14
- 210000000987 immune system Anatomy 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 60
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 37
- 235000016709 nutrition Nutrition 0.000 claims abstract description 37
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 28
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 28
- 239000011701 zinc Substances 0.000 claims abstract description 28
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 26
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000011669 selenium Substances 0.000 claims abstract description 21
- 229910052711 selenium Inorganic materials 0.000 claims abstract description 21
- 108010024636 Glutathione Proteins 0.000 claims abstract description 17
- 229960003180 glutathione Drugs 0.000 claims abstract description 17
- 230000000694 effects Effects 0.000 claims abstract description 11
- 229960005486 vaccine Drugs 0.000 claims abstract description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 36
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 32
- 235000006708 antioxidants Nutrition 0.000 claims description 25
- 229940088594 vitamin Drugs 0.000 claims description 25
- 229930003231 vitamin Natural products 0.000 claims description 25
- 235000013343 vitamin Nutrition 0.000 claims description 25
- 239000011782 vitamin Substances 0.000 claims description 25
- 230000003078 antioxidant effect Effects 0.000 claims description 24
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 17
- 235000019165 vitamin E Nutrition 0.000 claims description 17
- 239000011709 vitamin E Substances 0.000 claims description 17
- 229930003427 Vitamin E Natural products 0.000 claims description 16
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 16
- 229940046009 vitamin E Drugs 0.000 claims description 16
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 15
- 235000019154 vitamin C Nutrition 0.000 claims description 15
- 239000011718 vitamin C Substances 0.000 claims description 15
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 14
- 229930003268 Vitamin C Natural products 0.000 claims description 14
- 235000019155 vitamin A Nutrition 0.000 claims description 14
- 239000011719 vitamin A Substances 0.000 claims description 14
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 13
- 229940045997 vitamin a Drugs 0.000 claims description 13
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 8
- 229910052751 metal Inorganic materials 0.000 claims description 7
- 239000002184 metal Substances 0.000 claims description 7
- 150000002739 metals Chemical class 0.000 claims description 5
- 238000000034 method Methods 0.000 abstract description 13
- 241000124008 Mammalia Species 0.000 abstract description 10
- 238000002649 immunization Methods 0.000 abstract description 5
- 230000003053 immunization Effects 0.000 abstract description 5
- 230000028993 immune response Effects 0.000 abstract description 4
- 238000002255 vaccination Methods 0.000 description 18
- 102000003792 Metallothionein Human genes 0.000 description 11
- 108090000157 Metallothionein Proteins 0.000 description 11
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 7
- 229940065287 selenium compound Drugs 0.000 description 7
- 150000003343 selenium compounds Chemical class 0.000 description 7
- 229960000984 tocofersolan Drugs 0.000 description 7
- 208000029560 autism spectrum disease Diseases 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 5
- 229910052753 mercury Inorganic materials 0.000 description 5
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 4
- 230000007613 environmental effect Effects 0.000 description 4
- 229910001385 heavy metal Inorganic materials 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000004014 plasticizer Substances 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000008774 maternal effect Effects 0.000 description 3
- 238000011287 therapeutic dose Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
- 229910000497 Amalgam Inorganic materials 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- ZZIFPJZQHRJERU-WDSKDSINSA-N Glu-Cys-Gly Chemical group OC(=O)CC[C@H](N)C(=O)N[C@@H](CS)C(=O)NCC(O)=O ZZIFPJZQHRJERU-WDSKDSINSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 231100000783 metal toxicity Toxicity 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 229960003471 retinol Drugs 0.000 description 2
- 235000020944 retinol Nutrition 0.000 description 2
- 239000011607 retinol Substances 0.000 description 2
- -1 selenate anions Chemical class 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- RJFAYQIBOAGBLC-UHFFFAOYSA-N 2-amino-4-methylselanyl-butanoic acid Chemical compound C[Se]CCC(N)C(O)=O RJFAYQIBOAGBLC-UHFFFAOYSA-N 0.000 description 1
- FDKWRPBBCBCIGA-UHFFFAOYSA-N 2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]CC(N)C(O)=O FDKWRPBBCBCIGA-UHFFFAOYSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010010957 Copper deficiency Diseases 0.000 description 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
- 108010010256 Dietary Proteins Proteins 0.000 description 1
- 102000015781 Dietary Proteins Human genes 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 235000004251 balanced diet Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 229960002380 dibutyl phthalate Drugs 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- PLDSRBDSTIMSQF-UHFFFAOYSA-N methanediselenoic acid Chemical class [SeH]C=[Se] PLDSRBDSTIMSQF-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000023105 myelination Effects 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 230000001703 neuroimmune Effects 0.000 description 1
- 230000009207 neuronal maturation Effects 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000009021 pre-vaccination Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000033458 reproduction Effects 0.000 description 1
- 229940100381 rhogam Drugs 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 229940082569 selenite Drugs 0.000 description 1
- MCAHWIHFGHIESP-UHFFFAOYSA-L selenite(2-) Chemical compound [O-][Se]([O-])=O MCAHWIHFGHIESP-UHFFFAOYSA-L 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000004246 zinc acetate Substances 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to a therapeutic composition and in greater detail it relates to a nutritional compound for beneficially supporting the immune function of a mammal, and in particular for the human immune system in the event of stressors such as immunization or illness.
- autistic patients are thought to have defective metallothionein (MT) proteins which normally regulate copper, zinc, heavy metals, gluten and casein digestion, and neuronal development. Elevated copper/zinc ratios are characteristic of ASD, but recently it has also become possible to measure MT proteins in red blood cells directly. Clinical reports already suggest that many autistic children test low on MT protein, and classic features of autism can indeed result from a genetically weakened MT system. Gastrointestinal dysfunction from metal toxicity may prevent these patients from breaking down dietary protein into required amino acids needed for MT protein synthesis, and from maintaining normal intestinal flora. Since MT is directly involved in the neuronal maturation of the brain, the timing of any environmental insults is critically important, and calls attention once again to the vaccination, as well as maternal mercury exposure and amalgam issues.
- MT metallothionein
- ASD is thought to be in part a disease of heavy metal induced oxidative stress with predisposing/permissive factors being the vulnerable MT system, vulnerability of the transmethylation and transsulfuration metabolic pathways, by which glutathione, and cysteine, two of the principal detoxifying substances found in the body are synthesized, and the presence of higher levels of testosterone in male children.
- Testosterone seems to potentiate the adverse effect of MT weakness on the brain, and appears to be partly responsible for slower synthesis of glutathione in males. These effects may account for the 4 to 1 ratio of males to females diagnosed with ASD.
- environmental insults such as mercury exposure, whether from vaccines, maternal exposure or diet occur, brain maturation and myelination may be compromised.
- the theory is that ASD patients do not have so much a damaged brain, but rather one that has not completely matured.
- a therapeutic treatment directed to removing ongoing environmental sources of heavy metals, chelating out existing tissue stores of heavy metals, supporting liver detoxification, preloading with zinc and augmenting nutrients, and then gradual introduction of MT and glutathione promoting nutrients.
- a treatment involving the process of detoxification of the central nervous system, and nutritional support for a weak MT protein and antioxidant buffering system is needed.
- the present invention comprises a therapeutic nutritional compound for reducing oxidative stress and supporting immune system function in a mammal, particularly a human baby or child. Additionally, the therapeutic nutritional compound can be used in conjunction with an immunization or vaccine regimen to reduce the undesirable effects caused by the metals in the vaccine.
- the therapeutic nutritional compound can include glutathione, selenium, zinc and antioxidants.
- the therapeutic nutritional compound consists essentially of on a weight percent basis of the following combined components, from about 20% to about 35% glutathione, less than 1% selenium and from about 60% to about 90% of one or more antioxidant vitamins. In a more preferred embodiment, the compound consists essentially of from about 65% to 75% of one or more antioxidant vitamins.
- the compound may further include zinc in an amount less than 1%. N-acetyl-cysteine may also be included in amount from 5% to 10%.
- the antioxidant vitamins included in the compound may include vitamin A, vitamin E, vitamin C and combinations thereof.
- the antioxidant vitamins comprise, by weight of the combined components, from about 20% to about 35% vitamin A, from about 2% to about 7% vitamin E, and from about 35% to about 50% vitamin C.
- a method of supporting the immune response of a mammal includes administering a therapeutic dose of a compound comprising on a weight percent basis of the combined following components from about 20% to about 35% glutathione, less than 1% selenium, from zero to less than 1% zinc and from about 60% to about 80% of an antioxidant vitamin or combination of antioxidant vitamins.
- the dose is between about 300 mg to about 500 mg, and preferably from about 350 mg to about 450 mg, and is administered to a human infant.
- about 1 dose is administered per day to an infant less than 6 months in age
- about 2 doses are administered per day to an infant between about 6 months to 12 months in age
- about 3 doses are administered per day to an infant between about 12 months to 36 months in age
- about 4 to about 5 doses are administered per day to an infant between about 36 months to 60 months in age.
- An additional embodiment includes a method of treating a mammal to increase an immune response in vaccination/immunization.
- the method includes administering a therapeutic dose of a compound comprising, on a weight percent basis of the combined following components, from about 20% to about 35% glutathione, less than 1% selenium, from zero to less than 1% zinc and from about 60% to about 80% of one or more antioxidant vitamins at least once before vaccination and at least once after being vaccinated.
- the mammal is administered a dose 1-7 days before vaccination, on the day of vaccination and 1-7 days after vaccination.
- the dose is typically administered to a human infant and/or young child.
- the present invention comprises a therapeutic nutritional compound that includes on a weight percent basis of the following combined components, from about 20% to about 35% glutathione, less than 1% selenium and from about 60% to about 80% of an antioxidant vitamin.
- the compound may further include zinc in an amount less than 1%.
- the therapeutic nutritional compound can be administered as part of a method for supporting the immune system of mammal in anticipation of vaccination/immunization.
- Various diseases and syndromes have been associated with vaccinations and it is believed that the present therapeutic nutritional compound and method of administering such greatly reduce the incidences of such consequences.
- the ingredients of the therapeutic nutritional compound are listed and claimed on a weight percentage of the combined claimed ingredients only. It is anticipated that other ingredients may be added to the compound mix such as fillers, emulsions and other components that are not to be included in the claimed percentages. The claimed percentages are only listed relative to claimed ingredients.
- the term “treat” refers to either preventing, or reducing the incidence of, the undesired occurrence.
- to treat immune suppression refers to either preventing the occurrence of this suppression or reducing the amount of such suppression.
- patient and “individual” are being used interchangeably and both refer to an animal.
- animal as used in this application refers to any warm-blooded mammal including, but not limited to, dogs, humans, monkeys, and apes.
- the term “about” refers to an amount varying from the stated range or number by a reasonable amount depending upon the context of use. Any numerical number or range specified in the specification should be considered to be modified by the term about.
- Dose and serving are used interchangeably and refer to the amount of the nutritional or pharmaceutical composition ingested by the patient in a single setting and designed to deliver effective amounts of the compound.
- a single dose or serving of the liquid nutritional powder should supply the amount discussed in the above in the Summary.
- the amount of the dose or serving should be a volume that a typical infant between 0 to 6 months can consume in one sitting. This amount can vary widely depending upon the age, weight, sex or medical condition of the patient.
- a single serving or dose of the compound nutritional product should be considered as encompassing a volume of 1-2 teaspoons adding water and sweetener of choice.
- Glutathione is a tripeptide and a major reducing agent in the mammalian body. Its chemical structure is GLU-CYS-GLY and its chemical name is glutamyl-cysteinyl-glycine. Like many other small peptides in the mammalian body, it is not synthesized by procedures involving DNA, RNA and ribosomes. Rather, it is synthesized from the amino acids available in the body by procedures utilizing enzymes and other body components such as adenosine triphosphate as an energy source. The glutathione used in the present compound is in a reduced form.
- Glutathione may be included in the compound in an amount between about 20% to about 35% and in a further embodiment in an amount between about 25% and 30% and in an additional embodiment in amount of about 27%.
- the composition of the compound dose may include between about 50 mg and 150 mg of glutathione and in a further embodiment between about 75 mg and 125 mg and in an additional embodiment about 100 mg.
- Selenium is one of numerous trace metals found in many foods.
- selenium may be employed as one of several non-toxic, water soluble organic or inorganic selenium compounds.
- Inorganic selenium compounds include aliphatic metal salts containing selenium in the form of selenite or selenate anions, however organic selenium compounds are normally less toxic than inorganic compounds.
- Other selenium compounds which may be mentioned by way of example include selenium cystine, selenium methionine, mono- and di-seleno carboxylic acids with about seven to eleven carbon atoms in the chain.
- Seleno Amino acid chelates are also useful. Any of these selenium compounds may be considered for use in the present invention as selenium precursors.
- selenium compounds set forth herein are not to be considered limitative.
- Other selenium compounds which exhibit the desired activity and are compatible with the other components in the mixture and are non-toxic, can be used in the practice of the invention. Many of them are available commercially.
- Selenium may be included in the compound in amount less than 1%. In a further embodiment selenium may be included in amounts less than 0.1%. In an additional embodiment, selenium may be included in amounts less than 0.01%. As an example, the composition of the compound dose may include between 10 and 50 micrograms for selenium and in a further embodiment between 20 and 40 micrograms and in an additional embodiment 30 micrograms.
- the antioxidant vitamins for use in the present compound include vitamins A, C and E.
- the antioxidant vitamin comprises, by weight of the combined components, from about 20% to about 30% vitamin A, from about 2% to about 7% vitamin E, and from about 35% to about 50% vitamin C.
- the antioxidant vitamin comprises, by weight of the combined components, about 27% vitamin A, about 5% vitamin E, and about 40% vitamin C.
- the composition of the compound dose may include between 100 mg to 250 mg of vitamin C, 10 mg and 30 mg of vitamin E and 50 mg and 150 mg of vitamin A.
- the compound dose may include 150 mg of vitamin C, 20 mg of vitamin E and 100 mg of vitamin A.
- vitamin E means a group of tocopherols that have the designations: .alpha.-, .beta.-, .delta.- and .gamma., that differ only in the number and position of methyl groups on the ring.
- the most active form of vitamin E, .alpha.-tocopherol is also the most widely distributed in nature.
- the synthetic material was found to have a slightly lower biological activity than the .alpha.-tocopherol from plants. Because of this phenomena, the natural occurring form has been designated RRR-.alpha.-tocopherol.
- vitamin E activity is expressed as RRR-.alpha.-tocopherol equivalents (-TEs).
- One .alpha.-TE is the activity of 1 mg of RRR-.alpha.-tocopherol.
- RRR-.alpha.-tocopherol is equivalent to 1.49 IU of vitamin E.
- the NAS-NRC RDA has been established at 10 mg-TE per day for adult males. Analyses of balanced diets indicate that the average daily intakes of .alpha.-TE range from 7 to 11 mg. Adults tolerate oral doses of 100 to 800 mg/day without symptoms or biochemical evidence of toxicity.
- vitamin C means ascorbic acid. Ascorbic acid intake for adult males between the ages of 20 and 29 years was found to average 121 mg per day (U.S. Dept. of Health and Human Services, 1994). The NAS-NRC RDA for ascorbic acid has been set at 60 mg for adult males. Many people habitually ingest 1000 mg per day of ascorbic acid without developing apparent toxic manifestations.
- vitamin A is used to include retinol and other chemically similar compounds referred to as retinoids. Beta-carotene and other carotenoids are provitamins and are only turned into retinol as the body requires.
- Zinc is an essential part of more than 100 enzymes involved in digestion, metabolism, reproduction and wound healing.
- the RDA for zinc is approximately 15 mg.
- a 200 mg dosage of zinc per day, although well tolerated, has been shown to have potential side effects such as anemia.
- the anemia associated with high dosage zinc intake is attributable to copper deficiency.
- Zinc is preferred in the form of an acetate.
- the zinc component may also be an oxide, which is well tolerated in the digestive system.
- other forms of zinc such as for example zinc gluconate may alternatively be used or be used in combination with zinc acetate in the subject composition.
- zinc represents approximately less than 1 percent, in a further embodiment between about 0.2 to 0.9 percent, and an additional embodiment at about 0.7 percent by weight of each dose of the claimed ingredients.
- the composition of the compound dose may include between about 1.5 mg and 3.5 mg of zinc and in a further embodiment between about 2.0 mg and 3.0 mg of zinc and in an additional embodiment about 2.5 mg of zinc.
- the present inventive subject further matter contemplates the use of biologically-acceptable carriers which may be prepared from a wide range of materials.
- materials include diluents, binders and adhesives, lubricants, plasticizers, disintegrants, colorants, bulking substances, flavorings, sweeteners and miscellaneous materials such as buffers and adsorbents in order to prepare a particular medicated composition.
- Binders may be selected from a wide range of materials such as hydroxypropylmethylcellulose, ethylcellulose, or other suitable cellulose derivatives, povidone, acrylic and methacrylic acid co-polymers, pharmaceutical glaze, gums, milk derivatives, such as whey, starches, and derivatives, as well as other conventional binders well known to persons skilled in the art.
- Exemplary non-limiting solvents are water, ethanol, isopropyl alcohol, methylene chloride or mixtures and combinations thereof.
- Exemplary non-limiting bulking substances include sugar, lactose, gelatin, starch, and silicon dioxide.
- the plasticizers may be selected from the group consisting of diethyl phthalate, diethyl sebacate, triethyl citrate, cronotic acid, propylene glycol, butyl phthalate, dibutyl sebacate, caster oil and mixtures thereof, without limitation.
- the plasticizers may be hydrophobic as well as hydrophilic in nature.
- Water-insoluble hydrophobic substances, such as diethyl phthalate, diethyl sebacate and caster oil are used to delay the release of water-soluble vitamins, such as vitamin C.
- hydrophilic plasticizers are used when water-insoluble vitamins are employed which aid in dissolving the encapsulated film, making channels in the surface, which aid in nutritional composition release.
- An additional embodiment includes a method of treating a mammal to support an immune response in vaccination.
- the method includes administering a therapeutic dose of a compound comprising on a weight percent basis of the combined following components from about 20% to about 35% glutathione, less than 1% selenium, from zero to less than 1% zinc and from about 60% to about 80% of one or more antioxidant vitamins at least once before vaccination and at least once after being vaccinated.
- the mammal is preferably administered a dose 2 days before vaccination, on the day of vaccination and 3 days after vaccination.
- the dose is typically administered to a human infant or child.
- the dose is between about 300 mg to about 500 mg of the claimed ingredients and is administered to a human infant or child. More preferably the dose is between about 350 mg to about 400 mg. In a further embodiment the dose is about 375 mg of the claimed ingredients.
- about 1 dose is administered per day to an infant less than 6 months in age
- about 2 doses are administered per day to an infant between about 6 months to 12 months in age
- about 3 doses are administered per day to an infant between about 12 months to 36 months in age
- about 4 to about 5 doses are administered per day to an infant between about 36 months to 60 months in age.
- the pre-vaccination doses are administered 1-7 days before vaccination, at lest one dose is administered on the day of vaccination and the post-vaccination doses are administered 1-7 days after vaccination.
Abstract
Disclosed is a therapeutic nutritional compound for treating and supporting the immune response in a mammal, particularly a human baby or child, and the treatment method. Additionally, the therapeutic nutritional compound can be used in conjunction with a vaccine or immunization regimen to reduce the potential undesirable effects caused by other components of the vaccine. The therapeutic nutritional compound can include glutathione, selenium, zinc and antioxidants.
Description
- The present invention relates to a therapeutic composition and in greater detail it relates to a nutritional compound for beneficially supporting the immune function of a mammal, and in particular for the human immune system in the event of stressors such as immunization or illness.
- There has been a rise in the incidence of Autistic Spectrum Disorder (ASD) since the mid 1980s. This increase cannot be attributed or explained by genetic factors alone. Thus, some have concluded that there is an environmental cause or factor to such disorders. One such factor under suspicion is metal toxicity and especially mercury. Apparently, some children are genetically predisposed to excessive vulnerability and toxicity to mercury. Cumulative exposures from maternal amalgams, Rho D shots for Rh incompatibility, seafood, and especially metal-containing vaccinations take them beyond their tolerance point and into neurotoxic, neurobiologic, neuroimmune and neurometabolic consequence manifesting, to variable degrees as abnormal behaviors, abnormal immune function, and abnormal gut function. Fully 60% of autistic children have mothers who are Rh negative (whereas only 8% of women in the general population are Rh negative), and who received the heavily mercury laden Rhogam shots during pregnancy.
- Additionally, autistic patients are thought to have defective metallothionein (MT) proteins which normally regulate copper, zinc, heavy metals, gluten and casein digestion, and neuronal development. Elevated copper/zinc ratios are characteristic of ASD, but recently it has also become possible to measure MT proteins in red blood cells directly. Clinical reports already suggest that many autistic children test low on MT protein, and classic features of autism can indeed result from a genetically weakened MT system. Gastrointestinal dysfunction from metal toxicity may prevent these patients from breaking down dietary protein into required amino acids needed for MT protein synthesis, and from maintaining normal intestinal flora. Since MT is directly involved in the neuronal maturation of the brain, the timing of any environmental insults is critically important, and calls attention once again to the vaccination, as well as maternal mercury exposure and amalgam issues.
- ASD is thought to be in part a disease of heavy metal induced oxidative stress with predisposing/permissive factors being the vulnerable MT system, vulnerability of the transmethylation and transsulfuration metabolic pathways, by which glutathione, and cysteine, two of the principal detoxifying substances found in the body are synthesized, and the presence of higher levels of testosterone in male children. Testosterone seems to potentiate the adverse effect of MT weakness on the brain, and appears to be partly responsible for slower synthesis of glutathione in males. These effects may account for the 4 to 1 ratio of males to females diagnosed with ASD. When environmental insults such as mercury exposure, whether from vaccines, maternal exposure or diet occur, brain maturation and myelination may be compromised. The theory is that ASD patients do not have so much a damaged brain, but rather one that has not completely matured.
- Thus, what is needed is a therapeutic treatment directed to removing ongoing environmental sources of heavy metals, chelating out existing tissue stores of heavy metals, supporting liver detoxification, preloading with zinc and augmenting nutrients, and then gradual introduction of MT and glutathione promoting nutrients. A treatment involving the process of detoxification of the central nervous system, and nutritional support for a weak MT protein and antioxidant buffering system is needed.
- The present invention comprises a therapeutic nutritional compound for reducing oxidative stress and supporting immune system function in a mammal, particularly a human baby or child. Additionally, the therapeutic nutritional compound can be used in conjunction with an immunization or vaccine regimen to reduce the undesirable effects caused by the metals in the vaccine. The therapeutic nutritional compound can include glutathione, selenium, zinc and antioxidants.
- In greater detail, the therapeutic nutritional compound consists essentially of on a weight percent basis of the following combined components, from about 20% to about 35% glutathione, less than 1% selenium and from about 60% to about 90% of one or more antioxidant vitamins. In a more preferred embodiment, the compound consists essentially of from about 65% to 75% of one or more antioxidant vitamins. The compound may further include zinc in an amount less than 1%. N-acetyl-cysteine may also be included in amount from 5% to 10%.
- The antioxidant vitamins included in the compound may include vitamin A, vitamin E, vitamin C and combinations thereof. Typically, the antioxidant vitamins comprise, by weight of the combined components, from about 20% to about 35% vitamin A, from about 2% to about 7% vitamin E, and from about 35% to about 50% vitamin C.
- In a further embodiment, a method of supporting the immune response of a mammal is provided. The method includes administering a therapeutic dose of a compound comprising on a weight percent basis of the combined following components from about 20% to about 35% glutathione, less than 1% selenium, from zero to less than 1% zinc and from about 60% to about 80% of an antioxidant vitamin or combination of antioxidant vitamins. Typically, the dose is between about 300 mg to about 500 mg, and preferably from about 350 mg to about 450 mg, and is administered to a human infant. In dosing, about 1 dose is administered per day to an infant less than 6 months in age, about 2 doses are administered per day to an infant between about 6 months to 12 months in age, about 3 doses are administered per day to an infant between about 12 months to 36 months in age and about 4 to about 5 doses are administered per day to an infant between about 36 months to 60 months in age.
- An additional embodiment includes a method of treating a mammal to increase an immune response in vaccination/immunization. The method includes administering a therapeutic dose of a compound comprising, on a weight percent basis of the combined following components, from about 20% to about 35% glutathione, less than 1% selenium, from zero to less than 1% zinc and from about 60% to about 80% of one or more antioxidant vitamins at least once before vaccination and at least once after being vaccinated. The mammal is administered a dose 1-7 days before vaccination, on the day of vaccination and 1-7 days after vaccination. The dose is typically administered to a human infant and/or young child.
- The present invention comprises a therapeutic nutritional compound that includes on a weight percent basis of the following combined components, from about 20% to about 35% glutathione, less than 1% selenium and from about 60% to about 80% of an antioxidant vitamin. The compound may further include zinc in an amount less than 1%.
- The therapeutic nutritional compound can be administered as part of a method for supporting the immune system of mammal in anticipation of vaccination/immunization. Various diseases and syndromes have been associated with vaccinations and it is believed that the present therapeutic nutritional compound and method of administering such greatly reduce the incidences of such consequences.
- The ingredients of the therapeutic nutritional compound are listed and claimed on a weight percentage of the combined claimed ingredients only. It is anticipated that other ingredients may be added to the compound mix such as fillers, emulsions and other components that are not to be included in the claimed percentages. The claimed percentages are only listed relative to claimed ingredients.
- As used in this application, the term “treat” refers to either preventing, or reducing the incidence of, the undesired occurrence. For example, to treat immune suppression refers to either preventing the occurrence of this suppression or reducing the amount of such suppression. The terms “patient” and “individual” are being used interchangeably and both refer to an animal. The term “animal” as used in this application refers to any warm-blooded mammal including, but not limited to, dogs, humans, monkeys, and apes. As used in the application the term “about” refers to an amount varying from the stated range or number by a reasonable amount depending upon the context of use. Any numerical number or range specified in the specification should be considered to be modified by the term about.
- “Dose” and “serving” are used interchangeably and refer to the amount of the nutritional or pharmaceutical composition ingested by the patient in a single setting and designed to deliver effective amounts of the compound. As will be readily apparent to those skilled in the art, a single dose or serving of the liquid nutritional powder should supply the amount discussed in the above in the Summary. The amount of the dose or serving should be a volume that a typical infant between 0 to 6 months can consume in one sitting. This amount can vary widely depending upon the age, weight, sex or medical condition of the patient. However as a general guideline, a single serving or dose of the compound nutritional product should be considered as encompassing a volume of 1-2 teaspoons adding water and sweetener of choice.
- Glutathione
- Glutathione is a tripeptide and a major reducing agent in the mammalian body. Its chemical structure is GLU-CYS-GLY and its chemical name is glutamyl-cysteinyl-glycine. Like many other small peptides in the mammalian body, it is not synthesized by procedures involving DNA, RNA and ribosomes. Rather, it is synthesized from the amino acids available in the body by procedures utilizing enzymes and other body components such as adenosine triphosphate as an energy source. The glutathione used in the present compound is in a reduced form.
- Glutathione may be included in the compound in an amount between about 20% to about 35% and in a further embodiment in an amount between about 25% and 30% and in an additional embodiment in amount of about 27%. As an example, the composition of the compound dose may include between about 50 mg and 150 mg of glutathione and in a further embodiment between about 75 mg and 125 mg and in an additional embodiment about 100 mg.
- Selenium
- Selenium is one of numerous trace metals found in many foods. In the compositions of this invention, selenium may be employed as one of several non-toxic, water soluble organic or inorganic selenium compounds. Inorganic selenium compounds include aliphatic metal salts containing selenium in the form of selenite or selenate anions, however organic selenium compounds are normally less toxic than inorganic compounds. Other selenium compounds which may be mentioned by way of example include selenium cystine, selenium methionine, mono- and di-seleno carboxylic acids with about seven to eleven carbon atoms in the chain. Seleno Amino acid chelates are also useful. Any of these selenium compounds may be considered for use in the present invention as selenium precursors.
- It will be understood, however, that the particular forms of selenium compounds set forth herein are not to be considered limitative. Other selenium compounds, which exhibit the desired activity and are compatible with the other components in the mixture and are non-toxic, can be used in the practice of the invention. Many of them are available commercially.
- Selenium may be included in the compound in amount less than 1%. In a further embodiment selenium may be included in amounts less than 0.1%. In an additional embodiment, selenium may be included in amounts less than 0.01%. As an example, the composition of the compound dose may include between 10 and 50 micrograms for selenium and in a further embodiment between 20 and 40 micrograms and in an additional embodiment 30 micrograms.
- Antioxidant Vitamins
- The antioxidant vitamins for use in the present compound include vitamins A, C and E. The antioxidant vitamin comprises, by weight of the combined components, from about 20% to about 30% vitamin A, from about 2% to about 7% vitamin E, and from about 35% to about 50% vitamin C. In a further embodiment, the antioxidant vitamin comprises, by weight of the combined components, about 27% vitamin A, about 5% vitamin E, and about 40% vitamin C.
- As an example, the composition of the compound dose may include between 100 mg to 250 mg of vitamin C, 10 mg and 30 mg of vitamin E and 50 mg and 150 mg of vitamin A. In a further example, the compound dose may include 150 mg of vitamin C, 20 mg of vitamin E and 100 mg of vitamin A.
- The term “vitamin E” means a group of tocopherols that have the designations: .alpha.-, .beta.-, .delta.- and .gamma., that differ only in the number and position of methyl groups on the ring. The most active form of vitamin E, .alpha.-tocopherol, is also the most widely distributed in nature. When .alpha.-tocopherol was first synthesized, the synthetic material was found to have a slightly lower biological activity than the .alpha.-tocopherol from plants. Because of this phenomena, the natural occurring form has been designated RRR-.alpha.-tocopherol. For dietary purposes, vitamin E activity is expressed as RRR-.alpha.-tocopherol equivalents (-TEs). One .alpha.-TE is the activity of 1 mg of RRR-.alpha.-tocopherol. One mg of RRR-.alpha.-tocopherol is equivalent to 1.49 IU of vitamin E. The NAS-NRC RDA has been established at 10 mg-TE per day for adult males. Analyses of balanced diets indicate that the average daily intakes of .alpha.-TE range from 7 to 11 mg. Adults tolerate oral doses of 100 to 800 mg/day without symptoms or biochemical evidence of toxicity.
- The term “vitamin C” means ascorbic acid. Ascorbic acid intake for adult males between the ages of 20 and 29 years was found to average 121 mg per day (U.S. Dept. of Health and Human Services, 1994). The NAS-NRC RDA for ascorbic acid has been set at 60 mg for adult males. Many people habitually ingest 1000 mg per day of ascorbic acid without developing apparent toxic manifestations.
- The term “vitamin A” is used to include retinol and other chemically similar compounds referred to as retinoids. Beta-carotene and other carotenoids are provitamins and are only turned into retinol as the body requires.
- Zinc
- Zinc is an essential part of more than 100 enzymes involved in digestion, metabolism, reproduction and wound healing. The RDA for zinc is approximately 15 mg. A 200 mg dosage of zinc per day, although well tolerated, has been shown to have potential side effects such as anemia. The anemia associated with high dosage zinc intake is attributable to copper deficiency. Zinc is preferred in the form of an acetate. The zinc component may also be an oxide, which is well tolerated in the digestive system. However, other forms of zinc such as for example zinc gluconate may alternatively be used or be used in combination with zinc acetate in the subject composition.
- Accordingly, zinc represents approximately less than 1 percent, in a further embodiment between about 0.2 to 0.9 percent, and an additional embodiment at about 0.7 percent by weight of each dose of the claimed ingredients. As an example, the composition of the compound dose may include between about 1.5 mg and 3.5 mg of zinc and in a further embodiment between about 2.0 mg and 3.0 mg of zinc and in an additional embodiment about 2.5 mg of zinc.
- The present inventive subject further matter contemplates the use of biologically-acceptable carriers which may be prepared from a wide range of materials. Without being limited thereto, such materials include diluents, binders and adhesives, lubricants, plasticizers, disintegrants, colorants, bulking substances, flavorings, sweeteners and miscellaneous materials such as buffers and adsorbents in order to prepare a particular medicated composition.
- Binders may be selected from a wide range of materials such as hydroxypropylmethylcellulose, ethylcellulose, or other suitable cellulose derivatives, povidone, acrylic and methacrylic acid co-polymers, pharmaceutical glaze, gums, milk derivatives, such as whey, starches, and derivatives, as well as other conventional binders well known to persons skilled in the art. Exemplary non-limiting solvents are water, ethanol, isopropyl alcohol, methylene chloride or mixtures and combinations thereof. Exemplary non-limiting bulking substances include sugar, lactose, gelatin, starch, and silicon dioxide.
- The plasticizers may be selected from the group consisting of diethyl phthalate, diethyl sebacate, triethyl citrate, cronotic acid, propylene glycol, butyl phthalate, dibutyl sebacate, caster oil and mixtures thereof, without limitation. As is evident, the plasticizers may be hydrophobic as well as hydrophilic in nature. Water-insoluble hydrophobic substances, such as diethyl phthalate, diethyl sebacate and caster oil are used to delay the release of water-soluble vitamins, such as vitamin C. In contrast, hydrophilic plasticizers are used when water-insoluble vitamins are employed which aid in dissolving the encapsulated film, making channels in the surface, which aid in nutritional composition release.
- Method
- An additional embodiment includes a method of treating a mammal to support an immune response in vaccination. The method includes administering a therapeutic dose of a compound comprising on a weight percent basis of the combined following components from about 20% to about 35% glutathione, less than 1% selenium, from zero to less than 1% zinc and from about 60% to about 80% of one or more antioxidant vitamins at least once before vaccination and at least once after being vaccinated. The mammal is preferably administered a dose 2 days before vaccination, on the day of vaccination and 3 days after vaccination. The dose is typically administered to a human infant or child.
- Typically, the dose is between about 300 mg to about 500 mg of the claimed ingredients and is administered to a human infant or child. More preferably the dose is between about 350 mg to about 400 mg. In a further embodiment the dose is about 375 mg of the claimed ingredients. In dosing, about 1 dose is administered per day to an infant less than 6 months in age, about 2 doses are administered per day to an infant between about 6 months to 12 months in age, about 3 doses are administered per day to an infant between about 12 months to 36 months in age and about 4 to about 5 doses are administered per day to an infant between about 36 months to 60 months in age. The pre-vaccination doses are administered 1-7 days before vaccination, at lest one dose is administered on the day of vaccination and the post-vaccination doses are administered 1-7 days after vaccination.
- While there is described herein certain specific embodiments of the present invention, it will be manifest to those skilled in the art that various modifications may be made without departing from the spirit and scope of the underlying inventive concept and that the same is not limited to the particular forms herein described except insofar as indicated by the scope of the appended claims.
Claims (20)
1. A therapeutic nutritional compound effective in reducing undesirable effects resulting from the presence of metals in vaccines administered to infants, the compound consisting essentially of the following components, on a weight percent basis by weight of the combined components:
from about 20% to about 35% glutathione;
less than 1% selenium; and
from about 60% to about 80% of one or more antioxidant vitamins.
2. The therapeutic nutritional compound of claim 1 , wherein the compound further includes zinc as a component in an amount less than 1% by weight of the combined components.
3. The therapeutic nutritional compound of claim 1 , wherein the antioxidant vitamin is selected from the group consisting of vitamin A, vitamin E, vitamin C and combinations thereof.
4. The therapeutic nutritional compound of claim 1 , wherein glutathione is included in an amount of from about 25% to about 30%.
5. The therapeutic nutritional compound of claim 1 , wherein the antioxidant vitamin is included in an amount of from 65% to 75%.
6. The therapeutic nutritional compound of claim 1 , wherein the one or more antioxidant vitamins comprises, by weight of the combined components:
from about 20% to about 30% vitamin A;
from about 2% to about 7% vitamin E; and
from about 35% to about 50% vitamin C.
7. The therapeutic nutritional compound of claim 1 , wherein selenium is included in an amount less than 0.1% by weight of the combined components.
8. The therapeutic nutritional compound of claim 2 , wherein zinc is included as a component in an amount less than 0.1% by weight of the combined components.
9. The therapeutic nutritional compound of claim 5 , wherein the compound further includes zinc as a component in an amount less than 1% by weight of the combined components.
10. The therapeutic nutritional compound of claim 5 wherein glutathione is included in an amount of from about 25% to about 30%.
11. The therapeutic nutritional compound of claim 5 , wherein selenium is included in an amount less than 0.1% by weight of the combined components.
12. The therapeutic nutritional compound of claim 5 , wherein zinc is further included in an amount less than 0.1% by weight of the combined components.
13. A therapeutic nutritional compound consisting essentially of the following components, on a weight percent basis by weight of the combined components:
from about 20% to about 35% glutathione;
less than 1% selenium; and
from about 60% to about 80% of one or more antioxidant vitamins;
wherein said compound is effective in reducing undesirable effects resulting from the presence of metals in vaccines administered to infants when said compound is administered prior to administration of said vaccine.
14. The therapeutic nutritional compound of claim 13 , wherein the compound further includes zinc as a component in an amount less than 1% by weight of the combined components.
15. The therapeutic nutritional compound of claim 13 , wherein the antioxidant vitamin is selected from the group consisting of vitamin A, vitamin E, vitamin C and combinations thereof.
16. The therapeutic nutritional compound of claim 13 , wherein the one or more antioxidant vitamins comprises, by weight of the combined components:
from about 20% to about 30% vitamin A;
from about 2% to about 7% vitamin E; and
from about 35% to about 50% vitamin C.
17. The therapeutic nutritional compound of claim 14 , wherein the antioxidant vitamin is selected from the group consisting of vitamin A, vitamin E, vitamin C and combinations thereof.
18. The therapeutic nutritional compound of claim 14 , wherein the one or more antioxidant vitamins comprises, by weight of the combined components:
from about 20% to about 30% vitamin A;
from about 2% to about 7% vitamin E; and
from about 35% to about 50% vitamin C.
19. A therapeutic nutritional compound effective in reducing undesirable effects resulting from the presence of metals in vaccines administered to infants, the compound consisting of the following components, on a weight percent basis by weight of the combined components:
from about 20% to about 35% glutathione;
less than 1% selenium; and
from about 60% to about 80% of one or more antioxidant vitamins.
20. The therapeutic nutritional compound of claim 19 , wherein the compound further includes zinc as a component in an amount less than 1% by weight of the combined components.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/825,407 US20070275092A1 (en) | 2005-09-09 | 2007-07-06 | Therapeutic composition supporting the immune system |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/223,533 US7304038B2 (en) | 2005-09-09 | 2005-09-09 | Therapeutic composition and method of supporting the immune system |
US11/825,407 US20070275092A1 (en) | 2005-09-09 | 2007-07-06 | Therapeutic composition supporting the immune system |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/223,533 Division US7304038B2 (en) | 2005-09-09 | 2005-09-09 | Therapeutic composition and method of supporting the immune system |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070275092A1 true US20070275092A1 (en) | 2007-11-29 |
Family
ID=37855470
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/223,533 Active US7304038B2 (en) | 2005-09-09 | 2005-09-09 | Therapeutic composition and method of supporting the immune system |
US11/825,407 Abandoned US20070275092A1 (en) | 2005-09-09 | 2007-07-06 | Therapeutic composition supporting the immune system |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/223,533 Active US7304038B2 (en) | 2005-09-09 | 2005-09-09 | Therapeutic composition and method of supporting the immune system |
Country Status (1)
Country | Link |
---|---|
US (2) | US7304038B2 (en) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5488039A (en) * | 1994-01-10 | 1996-01-30 | Abbott Laboratories | Method for the production of an enteral formula containing ribo-nucleotides |
US5562910A (en) * | 1989-09-25 | 1996-10-08 | University Of Utah Research Foundation | Vaccine compositions and method for enhancing an immune response |
US5785978A (en) * | 1994-11-15 | 1998-07-28 | Osmotics Corporation | Skin care compositions and methods |
US5875798A (en) * | 1997-09-23 | 1999-03-02 | Advanced Medical Instruments, Inc. | Therapeutic toothpick for treating oral and systemic diseases |
US5948443A (en) * | 1996-02-23 | 1999-09-07 | Medical Doctor's Research Institute, Inc. | Acetylsalicylic acid and micronutrient supplementation for nutritional losses and coronary heart disease |
US6090414A (en) * | 1970-05-20 | 2000-07-18 | Life Science Labs, Inc. | Method and composition to reduce cancer incidence |
US6469024B2 (en) * | 2000-05-11 | 2002-10-22 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline analogs useful as growth hormone secretagogues |
US6630158B2 (en) * | 2000-10-31 | 2003-10-07 | Stiefel Laboratories, Inc. | Dietary supplement composition and method for improving and maintaining healthy skin |
-
2005
- 2005-09-09 US US11/223,533 patent/US7304038B2/en active Active
-
2007
- 2007-07-06 US US11/825,407 patent/US20070275092A1/en not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6090414A (en) * | 1970-05-20 | 2000-07-18 | Life Science Labs, Inc. | Method and composition to reduce cancer incidence |
US5562910A (en) * | 1989-09-25 | 1996-10-08 | University Of Utah Research Foundation | Vaccine compositions and method for enhancing an immune response |
US5488039A (en) * | 1994-01-10 | 1996-01-30 | Abbott Laboratories | Method for the production of an enteral formula containing ribo-nucleotides |
US5785978A (en) * | 1994-11-15 | 1998-07-28 | Osmotics Corporation | Skin care compositions and methods |
US5948443A (en) * | 1996-02-23 | 1999-09-07 | Medical Doctor's Research Institute, Inc. | Acetylsalicylic acid and micronutrient supplementation for nutritional losses and coronary heart disease |
US5875798A (en) * | 1997-09-23 | 1999-03-02 | Advanced Medical Instruments, Inc. | Therapeutic toothpick for treating oral and systemic diseases |
US6469024B2 (en) * | 2000-05-11 | 2002-10-22 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline analogs useful as growth hormone secretagogues |
US6630158B2 (en) * | 2000-10-31 | 2003-10-07 | Stiefel Laboratories, Inc. | Dietary supplement composition and method for improving and maintaining healthy skin |
Also Published As
Publication number | Publication date |
---|---|
US20070059383A1 (en) | 2007-03-15 |
US7304038B2 (en) | 2007-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2003266400C1 (en) | Leucine-enriched nutritional compositions | |
Yanagisawa | Zinc deficiency and clinical practice | |
TWI429405B (en) | Pediatric amino acid solution for parenteral nutrition | |
RU2420209C2 (en) | Long-term alimentation for cancer patient | |
JP3287842B2 (en) | Uses of arginine as an immunostimulant | |
JP2010180244A (en) | Inhibitor for liver cancer onset/progress | |
CA2234954A1 (en) | Multiple vitamin supplement composition | |
Prasad | Zinc in humans: health disorders and therapeutic effects | |
JP2021091739A (en) | Methods and compositions for treating thyroid-related medical conditions with reduced folates | |
ES2586930T3 (en) | Composition for the treatment of sterility | |
JPH04327537A (en) | Method of insuring sufficient intracellular glutathione in tissue | |
US7304038B2 (en) | Therapeutic composition and method of supporting the immune system | |
WO2007001006A1 (en) | Agent for ameliorating heavy metal-induced disorders, and medicinal composition, food and cosmetic containing the same | |
JP6625986B2 (en) | Cocoa polyphenols and their use in the treatment or prevention of eosinophilic esophagitis | |
JPH09110686A (en) | Macrophage nitrogen monoxide-producing sthenic agent | |
JP2005350371A (en) | Nutrient composition for hepatopathic patient | |
JP7184805B2 (en) | Betaine for prevention of obesity | |
Satoh et al. | Dietary therapy in two patients with vitamin B 12-unresponsive methylmalonic acidemia | |
JP3556757B2 (en) | Absorption-promoting saccharide composition | |
CA2232134A1 (en) | Use of threonine for the treatment of phenylketonuria | |
JP2001226285A (en) | Small intestine growth facilitative composition | |
WO2022091023A1 (en) | Combination of active ingredients, compositions containing it and their use to sustain and strengthen the immune system | |
CN113056206A (en) | Stability of vitamin D in beta-hydroxy-beta-methylbutyric acid (HMB) | |
CN113142553A (en) | Nutritional composition suitable for tumor patients, and preparation method and application thereof | |
Lagua | I. Chemical symbol for iodine. Iatrogenic. Tenn meaning" caused by medical treatment or diagnostic proce-dures." Iatrogenic malnutrition is an in-duced nutritional deficiency due to drug |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |